Patient-centric care

The ophthalmic community should always aim to provide care that considers individual patient preferences and needs. All clinical decisions should be guided by patient values, with the patient placed centrally in the treatment decision pathway. In this resource zone, we provide guidance on the following topics related to patient-centric care:

  • Suspending treatment of nAMD in cases of futility
  • Coordinated care in diabetic eye disease
  • Bilateral anti-VEGF treatment

Suspending treatment of nAMD in cases of futility

There is currently no clear consensus on how patients with neovascular age-related macular degeneration (nAMD) who respond poorly to anti-vascular endothelial growth factor (VEGF) therapy should be managed. Suboptimal responses to anti-VEGF may be a result of undertreatment or misdiagnosis of the underlying condition, as well as factors that may preclude continued treatment such as injection or drug-induced complications. The Vision Academy has developed an algorithm to help guide clinical decisions regarding switching or suspending anti-VEGF treatment in these cases.

Dr. David Wong describes the pressing need for expert guidance on switching or suspending treatment in patients with nAMD and suboptimal response to anti-VEGF

Coordinated care in diabetic eye disease

The management of patients with diabetes is a multidisciplinary effort, yet there is often a lack of communication between healthcare professionals of differing disciplines, as well as between these healthcare professionals and their diabetic patients. This can lead to the suboptimal management of diabetic eye disease and poor outcomes for patients.

View the expert presentations from EASD 2017

Download the Vision Academy EASD Symposium Slides: ‘Diabetic eye disease - A treatable complication of diabetes’

Download the Vision Academy EASD Symposium Slides: ‘The Association between DR and other complications of diabetes’

Bilateral anti-VEGF treatment

Many patients present with bilateral disease that is treatable with anti-VEGF agents. The Vision Academy advocates bilateral treatment, defined as the simultaneous or consecutive administration of anti-VEGF treatment during the same patient visit.

Mr. Ian Pearce describes how the Vision Academy Viewpoint provides guidance on the optimal management of patients with bilateral disease

Read the Vision Academy Viewpoint on bilateral treatment

Download the expert presentations from COPHy EU 2017